Natural killer (NK) cell profiles in blood and tumour in women with large and locally advanced breast cancer (LLABC) and their contribution to a pathological complete response (PCR) in the tumour following neoadjuvant chemotherapy (NAC): Differential restoration of blood profiles by NAC and surgery

Journal of Translational Medicine

Volumn 13, Issue 1, 2015, Pages

  Verma, Chandan ^a   Kaewkangsadan, Viriya ^a   Eremin, Jennifer M ^b   Cowley, Gerard P ^b   Ilyas, Mohammad ^a   El Sheemy, Mohamed A ^b   Eremin, Oleg ^a,b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b LINCOLN COUNTY HOSPITAL   (United Kingdom)

Author keywords

Breast cancer; Neoadjuvant chemotherapy; NK cells

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; GAMMA INTERFERON; GRANZYME B; INTERLEUKIN 2; NATURAL KILLER CELL RECEPTOR NKG2D; PERFORIN; TRANSFORMING GROWTH FACTOR BETA; CD56 ANTIGEN; CYTOKINE; GRANZYME; KLRK1 PROTEIN, HUMAN; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY K;

ADULT; ANTIBODY LABELING; ARTICLE; BLOOD SAMPLING; BREAST BIOPSY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURGERY; CELL ACTIVATION; CELL INFILTRATION; CELL MEDIATED CYTOTOXICITY; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INNATE IMMUNITY; LARGE AND LOCALLY ADVANCED BREAST CANCER; MASTECTOMY; NATURAL KILLER CELL; PROTEIN EXPRESSION; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; UPREGULATION; BIOPSY; BLOOD; BREAST; BREAST NEOPLASMS; CANCER STAGING; CARCINOMA IN SITU; CELL DEATH; IMMUNOLOGY; K-562 CELL LINE; LEUKOCYTE COUNT; METABOLISM; MIDDLE AGED; NEOADJUVANT THERAPY; PATHOLOGY; TREATMENT OUTCOME;

ANTIGENS, CD56; BIOPSY; BREAST; BREAST NEOPLASMS; CARCINOMA IN SITU; CELL DEATH; CYTOKINES; FEMALE; FLOW CYTOMETRY; GRANZYMES; HUMANS; K562 CELLS; KILLER CELLS, NATURAL; LEUKOCYTE COUNT; LYMPHOCYTES, TUMOR-INFILTRATING; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; PERFORIN; TREATMENT OUTCOME;

EID: 84930649133     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-015-0535-8     Document Type: Article

References (85)

1. Smyth MJ, Thia KY, Street SE, Cretney E, Trapani JA, Taniguchi M et al (2000) Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med 191(4):661-668
2. Dewan MZ, Terunuma H, Takada M, Tanaka Y, Abe H, Sata T et al (2007) Role of natural killer cells in hormone-independent rapid tumor formation and spontaneous metastasis of breast cancer cells in vivo. Breast Cancer Res Treat 104(3):267-275. 10.1007/s10549-006-9416-4.
3. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ (2011) Natural innate and adaptive immunity to cancer. Annu Rev Immunol 29:235-271. 10.1146/annurev-immunol-031210-101324.
4. Yang Q, Goding S, Hagenaars M, Carlos T, Albertsson P, Kuppen P et al (2006) Morphological appearance, content of extracellular matrix and vascular density of lung metastases predicts permissiveness to infiltration by adoptively transferred natural killer and T cells. Cancer Immunol Immunother 55(6):699-707. 10.1007/s00262-005-0043-4.
5. Sungur CM, Murphy WJ (2014) Positive and negative regulation by NK cells in cancer. Crit Rev Oncog 19(1-2):57-66
6. Bernardini G, Santoni A (2014) The pathophysiological role of chemokines in the regulation of NK cell tissue homing. Crit Rev Oncog 19(1-2):77-90
7. Roberti MP, Mordoh J, Levy EM (2012) Biological role of NK cells and immunotherapeutic approaches in breast cancer. Front Immunol 3:375. 10.3389/fimmu.2012.00375.
8. Strayer DR, Carter WA, Mayberry SD, Pequignot E, Brodsky I (1984) Low natural cytotoxicity of peripheral blood mononuclear cells in individuals with high familial incidences of cancer. Cancer Res 44(1):370-374
9. Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K (2000) Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet 356(9244):1795-1799. 10.1016/S0140-6736(00)03231-1.
10. Vaquer S, Jorda J, Lopez de la Osa E, Alvarez de los Heros J, Lopez-Garcia N, Alvarez de Mon M (1990) Clinical implications of natural killer (NK) cytotoxicity in patients with squamous cell carcinoma of the uterine cervix. Gynecol Oncol 36(1):90-92
11. Kondo E, Koda K, Takiguchi N, Oda K, Seike K, Ishizuka M et al (2003) Preoperative natural killer cell activity as a prognostic factor for distant metastasis following surgery for colon cancer. Dig Surg 20(5):445-451. 10.1159/000072714.
12. Takeuchi H, Maehara Y, Tokunaga E, Koga T, Kakeji Y, Sugimachi K (2001) Prognostic significance of natural killer cell activity in patients with gastric carcinoma: a multivariate analysis. Am J Gastroenterol 96(2):574-578. 10.1111/j.1572-0241.2001.03535.x.
13. Halama N, Braun M, Kahlert C, Spille A, Quack C, Rahbari N et al (2011) Natural killer cells are scarce in colorectal carcinoma tissue despite high levels of chemokines and cytokines. Clin Cancer Res 17(4):678-689. 10.1158/1078-0432.CCR-10-2173.
14. Mamessier E, Sylvain A, Bertucci F, Castellano R, Finetti P, Houvenaeghel G et al (2011) Human breast tumor cells induce self-tolerance mechanisms to avoid NKG2D-mediated and DNAM-mediated NK cell recognition. Cancer Res 71(21):6621-6632. 10.1158/0008-5472.CAN-11-0792.
15. Platonova S, Cherfils-Vicini J, Damotte D, Crozet L, Vieillard V, Validire P et al (2011) Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. Cancer Res 71(16):5412-5422. 10.1158/0008-5472.CAN-10-4179.
16. Eckl J, Buchner A, Prinz PU, Riesenberg R, Siegert SI, Kammerer R et al (2012) Transcript signature predicts tissue NK cell content and defines renal cell carcinoma subgroups independent of TNM staging. J Mol Med (Berl) 90(1):55-66. 10.1007/s00109-011-0806-7.
17. Sznurkowski JJ, Zawrocki A, Biernat W (2014) Subtypes of cytotoxic lymphocytes and natural killer cells infiltrating cancer nests correlate with prognosis in patients with vulvar squamous cell carcinoma. Cancer Immunol Immunother 63(3):297-303. 10.1007/s00262-013-1511-x.
18. Garrido F, Cabrera T, Aptsiauri N (2010) ''Hard'' and ''soft'' lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy. Int J Cancer 127(2):249-256. 10.1002/ijc.25270.
19. Hoglund P, Brodin P (2010) Current perspectives of natural killer cell education by MHC class I molecules. Nat Rev Immunol 10(10):724-734. 10.1038/nri2835.
20. Vivier E, Ugolini S, Blaise D, Chabannon C, Brossay L (2012) Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol 12(4):239-252. 10.1038/nri3174.
21. Desbois M, Rusakiewicz S, Locher C, Zitvogel L, Chaput N (2012) Natural killer cells in non-hematopoietic malignancies. Front Immunol 3:395. 10.3389/fimmu.2012.00395.
22. Bonavida B (2014) NK cell phenotypic and functional heterogeneities and molecular mechanisms of cytotoxicity. Crit Rev Oncog 19(1-2):21-45
23. Menard C, Blay JY, Borg C, Michiels S, Ghiringhelli F, Robert C et al (2009) Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients. Cancer Res 69(8):3563-3569. 10.1158/0008-5472.CAN-08-3807.
24. Ferlazzo G, Moretta L (2014) Dendritic cell editing by natural killer cells. Crit Rev Oncog 19(1-2):67-75
25. Garner WL, Minton JP, James AG, Hoffmann CC (1983) Human breast cancer and impaired NK cell function. J Surg Oncol 24(1):64-66
26. Konjevic G, Jurisic V, Spuzic I (2001) Association of NK cell dysfunction with changes in LDH characteristics of peripheral blood lymphocytes (PBL) in breast cancer patients. Breast Cancer Res Treat 66(3):255-263
27. Konjevic G, Radenkovic S, Srdic T, Jurisic V, Stamatovic L, Milovic M (2011) Association of decreased NK cell activity and IFNgamma expression with pSTAT dysregulation in breast cancer patients. J BUON 16(2):219-226
28. Eremin O, Coombs RR, Ashby J (1981) Lymphocytes infiltrating human breast cancers lack K-cell activity and show low levels of NK-cell activity. Br J Cancer 44(2):166-176
29. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G (2008) Immunological aspects of cancer chemotherapy. Nat Rev Immunol 8(1):59-73. 10.1038/nri2216.
30. Baxevanis CN, Perez SA, Papamichail M (2009) Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy. Cancer Immunol Immunother 58(3):317-324. 10.1007/s00262-008-0576-4.
31. Tsavaris N, Kosmas C, Vadiaka M, Kanelopoulos P, Boulamatsis D (2002) Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br J Cancer 87(1):21-27. 10.1038/sj.bjc.6600347.
32. Liu WM, Fowler DW, Smith P, Dalgleish AG (2010) Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses. Br J Cancer 102(1):115-123. 10.1038/sj.bjc.6605465.
33. Bubenik J (2004) MHC class I down-regulation: tumour escape from immune surveillance? (review). Int J Oncol 25(2):487-491
34. Walker LG, Eremin JM, Aloysius MM, Vassanasiri W, Walker MB, El-Sheemy M et al (2011) Effects on quality of life, anti-cancer responses, breast conserving surgery and survival with neoadjuvant docetaxel: a randomised study of sequential weekly versus three-weekly docetaxel following neoadjuvant doxorubicin and cyclophosphamide in women with primary breast cancer. BMC Cancer 11:179. 10.1186/1471-2407-11-179.
35. Brittenden J, Heys SD, Ross J, Park KG, Eremin O (1994) Natural cytotoxicity in breast cancer patients receiving neoadjuvant chemotherapy: effects of l-arginine supplementation. Eur J Surg Oncol 20(4):467-472
36. Khan AL, Richardson S, Drew J, Larsen F, Campbell M, Heys SD et al (1995) Polyadenylic-polyuridylic acid enhances the natural cell-mediated cytotoxicity in patients with breast cancer undergoing mastectomy. Surgery 118(3):531-538
37. Denkert C, Loibl S, Noske A, Roller M, Muller BM, Komor M et al (2010) Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28(1):105-113. 10.1200/JCO.2009.23.7370.
38. Murta EF, de Andrade JM, Falcao RP, Bighetti S (2000) Lymphocyte subpopulations in patients with advanced breast cancer submitted to neoadjuvant chemotherapy. Tumori 86(5):403-407
39. Muraro E, Martorelli D, Turchet E, Miolo G, Scalone S, Comaro E et al (2011) A different immunologic profile characterizes patients with HER-2-overexpressing and HER-2-negative locally advanced breast cancer: implications for immune-based therapies. Breast Cancer Res 13(6):R117. 10.1186/bcr3060.
40. Caras I, Grigorescu A, Stavaru C, Radu DL, Mogos I, Szegli G et al (2004) Evidence for immune defects in breast and lung cancer patients. Cancer Immunol Immunother 53(12):1146-1152. 10.1007/s00262-004-0556-2.
41. Mamessier E, Pradel LC, Thibult ML, Drevet C, Zouine A, Jacquemier J et al (2013) Peripheral blood NK cells from breast cancer patients are tumor-induced composite subsets. J Immunol 190(5):2424-2436. 10.4049/jimmunol.1200140.
42. Beitsch P, Lotzova E, Hortobagyi G, Pollock R (1994) Natural immunity in breast cancer patients during neoadjuvant chemotherapy and after surgery. Surg Oncol 3(4):211-219
43. Kaufmann M, von Minckwitz G, Mamounas EP, Cameron D, Carey LA, Cristofanilli M et al (2012) Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol 19(5):1508-1516. 10.1245/s10434-011-2108-2.
44. von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA et al (2012) Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30(15):1796-1804. 10.1200/JCO.2011.38.8595.
45. Eremin J, Cowley G, Walker LG, Murray E, Stovickova M, Eremin O (2015) Women with large (≥3 cm) and locally advanced breast cancers (T3, 4, N1, 2, M0) receiving neoadjuvant chemotherapy (NAC: cyclophosphamide, doxorubicin, docetaxel): addition of capecitabine improves 4-year disease-free survival. Springerplus Oncol 4:9. 10.1186/2193-1801-4-9.
46. Eremin O, Ashby J, Stephens JP (1978) Human natural cytotoxicity in the blood and lymphoid organs of healthy donors and patients with malignant disease. Int J Cancer 21(1):35-41
47. Mackay IR, Goodyear MD, Riglar C, Penschow J (1983) Effect on natural killer and antibody-dependent cellular cytotoxicity of adjuvant cytotoxic chemotherapy including melphalan in breast cancer. Cancer Immunol Immunother 16(2):98-100
48. Cunningham-Rundles S, Filippa DA, Braun DW Jr, Antonelli P, Ashikari H (1981) Natural cytotoxicity of peripheral blood lymphocytes and regional lymph node cells in breast cancer in women. J Natl Cancer Inst 67(3):585-590
49. White D, Jones DB, Cooke T, Kirkham N (1982) Natural killer (NK) activity in peripheral blood lymphocytes of patients with benign and malignant breast disease. Br J Cancer 46(4):611-616
50. Dewan MZ, Takada M, Terunuma H, Deng X, Ahmed S, Yamamoto N et al (2009) Natural killer activity of peripheral-blood mononuclear cells in breast cancer patients. Biomed Pharmacother 63(9):703-706. 10.1016/j.biopha.2009.02.003.
51. Konjevic G, Jurisic V, Jovic V, Vuletic A, Mirjacic Martinovic K, Radenkovic S et al (2012) Investigation of NK cell function and their modulation in different malignancies. Immunol Res 52(1-2):139-156. 10.1007/s12026-012-8285-7.
52. Standish LJ, Sweet ES, Novack J, Wenner CA, Bridge C, Nelson A et al (2008) Breast cancer and the immune system. J Soc Integr Oncol 6(4):158-168
53. Tichatschek E, Zielinski CC, Muller C, Sevelda P, Kubista E, Czerwenka K et al (1988) Long-term influence of adjuvant therapy on natural killer cell activity in breast cancer. Cancer Immunol Immunother 27(3):278-282
54. Chan OT, Yang LX (2000) The immunological effects of taxanes. Cancer Immunol Immunother 49(4-5):181-185
55. Cullen SP, Brunet M, Martin SJ (2010) Granzymes in cancer and immunity. Cell Death Differ 17(4):616-623. 10.1038/cdd.2009.206.
56. Ewen CL, Kane KP, Bleackley RC (2012) A quarter century of granzymes. Cell Death Differ 19(1):28-35. 10.1038/cdd.2011.153.
57. Lopez JA, Brennan AJ, Whisstock JC, Voskoboinik I, Trapani JA (2012) Protecting a serial killer: pathways for perforin trafficking and self-defence ensure sequential target cell death. Trends Immunol 33(8):406-412. 10.1016/j.it.2012.04.001.
58. Cao E, Zang X, Ramagopal UA, Mukhopadhaya A, Fedorov A, Fedorov E et al (2007) T cell immunoglobulin mucin-3 crystal structure reveals a galectin-9-independent ligand-binding surface. Immunity 26(3):311-321. 10.1016/j.immuni.2007.01.016.
59. Luthi AU, Cullen SP, McNeela EA, Duriez PJ, Afonina IS, Sheridan C et al (2009) Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity 31(1):84-98. 10.1016/j.immuni.2009.05.007.
60. Zhou L, Wang H, Zhong X, Jin Y, Mi QS, Sharma A et al (2008) The IL-10 and IFN-gamma pathways are essential to the potent immunosuppressive activity of cultured CD8+ NKT-like cells. Genome Biol 9(7):R119. 10.1186/gb-2008-9-7-r119.
61. Hodge G, Hodge S, Li-Liew C, Reynolds PN, Holmes M (2012) Increased natural killer T-like cells are a major source of pro-inflammatory cytokines and granzymes in lung transplant recipients. Respirology 17(1):155-163. 10.1111/j.1440-1843.2011.02075.x.
62. Piroozmand A, Hassan ZM (2010) Evaluation of natural killer cell activity in pre and post treated breast cancer patients. J Cancer Res Ther 6(4):478-481. 10.4103/0973-1482.77110.
63. Obeidy P, Sharland AF (2009) NKG2D and its ligands. Int J Biochem Cell Biol 41(12):2364-2367. 10.1016/j.biocel.2009.07.005.
64. Schwinn N, Vokhminova D, Sucker A, Textor S, Striegel S, Moll I et al (2009) Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells. Int J Cancer 124(7):1594-1604. 10.1002/ijc.24098.
65. Zafirova B, Wensveen FM, Gulin M, Polic B (2011) Regulation of immune cell function and differentiation by the NKG2D receptor. Cell Mol Life Sci 68(21):3519-3529. 10.1007/s00018-011-0797-0.
66. Zhang J, Basher F, Wu JD (2015) NKG2D ligands in tumor immunity: two sides of a coin. Front Immunol 6:97. 10.3389/fimmu.2015.00097.
67. Raulet DH (2003) Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 3(10):781-790. 10.1038/nri1199.
68. Diefenbach A, Jamieson AM, Liu SD, Shastri N, Raulet DH (2000) Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. Nat Immunol 1(2):119-126. 10.1038/77793.
69. Smyth MJ, Swann J, Cretney E, Zerafa N, Yokoyama WM, Hayakawa Y (2005) NKG2D function protects the host from tumor initiation. J Exp Med 202(5):583-588. 10.1084/jem.20050994.
70. Marcais A, Viel S, Grau M, Henry T, Marvel J, Walzer T (2013) Regulation of mouse NK cell development and function by cytokines. Front Immunol 4:450. 10.3389/fimmu.2013.00450.
71. Song H, Hur DY, Kim KE, Park H, Kim T, Kim CW et al (2006) IL-2/IL-18 prevent the down-modulation of NKG2D by TGF-beta in NK cells via the c-Jun N-terminal kinase (JNK) pathway. Cell Immunol 242(1):39-45. 10.1016/j.cellimm.2006.09.002.
72. Pende D, Rivera P, Marcenaro S, Chang CC, Biassoni R, Conte R et al (2002) Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res 62(21):6178-6186
73. de Kruijf EM, Sajet A, van Nes JG, Putter H, Smit VT, Eagle RA et al (2012) NKG2D ligand tumor expression and association with clinical outcome in early breast cancer patients: an observational study. BMC Cancer 12:24. 10.1186/1471-2407-12-24.
74. Verma C, Eremin JM, Robins A, Bennett AJ, Cowley GP, El-Sheemy MA et al (2013) Abnormal T regulatory cells (Tregs: FOXP3+, CTLA-4+), myeloid-derived suppressor cells (MDSCs: monocytic, granulocytic) and polarised T helper cell profiles (Th1, Th2, Th17) in women with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC) and surgery: failure of abolition of abnormal treg profile with treatment and correlation of treg levels with pathological response to NAC. J Transl Med 11:16. 10.1186/1479-5876-11-16.
75. Raulet DH, Vance RE, McMahon CW (2001) Regulation of the natural killer cell receptor repertoire. Annu Rev Immunol 19:291-330. 10.1146/annurev.immunol.19.1.291.
76. Trowsdale J, Parham P (2004) Mini-review: defense strategies and immunity-related genes. Eur J Immunol 34(1):7-17. 10.1002/eji.200324693.
77. Watzl C, Long EO (2003) Natural killer cell inhibitory receptors block actin cytoskeleton-dependent recruitment of 2B4 (CD244) to lipid rafts. J Exp Med 197(1):77-85
78. Hanaoka N, Jabri B, Dai Z, Ciszewski C, Stevens AM, Yee C et al (2010) NKG2D initiates caspase-mediated CD3zeta degradation and lymphocyte receptor impairments associated with human cancer and autoimmune disease. J Immunol 185(10):5732-5742. 10.4049/jimmunol.1002092.
79. Liu G, Lu S, Wang X, Page ST, Higano CS, Plymate SR et al (2013) Perturbation of NK cell peripheral homeostasis accelerates prostate carcinoma metastasis. J Clin Invest 123(10):4410-4422. 10.1172/JCI69369.
80. Madjd Z, Spendlove I, Moss R, Bevin S, Pinder SE, Watson NF et al (2007) Upregulation of MICA on high-grade invasive operable breast carcinoma. Cancer Immun 7:17
81. Pietra G, Manzini C, Rivara S, Vitale M, Cantoni C, Petretto A et al (2012) Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity. Cancer Res 72(6):1407-1415. 10.1158/0008-5472.CAN-11-2544.
82. Sconocchia G, Arriga R, Tornillo L, Terracciano L, Ferrone S, Spagnoli GC (2012) Melanoma cells inhibit NK cell functions. Cancer Res 72(20):5428-5429. 10.1158/0008-5472.CAN-12-1181(author reply 30) .
83. Oppenheim DE, Roberts SJ, Clarke SL, Filler R, Lewis JM, Tigelaar RE et al (2005) Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance. Nat Immunol 6(9):928-937. 10.1038/ni1239.
84. Fruci D, Lo Monaco E, Cifaldi L, Locatelli F, Tremante E, Benevolo M et al (2013) T and NK cells: two sides of tumor immunoevasion. J Transl Med 11(1):30. 10.1186/1479-5876-11-30.
85. Aloysius MM, Walker LG, Eremin O (2011) Cancer and the immune response, Chap 4. In: Eremin O, Sewell H (eds) Essential immunology for surgeons. Oxford OUP, Oxford, pp 236-300